Penumbra Inc
NYSE:PEN
Penumbra Inc
Total Receivables
Penumbra Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Penumbra Inc
NYSE:PEN
|
Total Receivables
$167.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Receivables
$2.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Receivables
$2.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Receivables
$4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Receivables
$6.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Receivables
$1.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
Penumbra Inc
Glance View
In the bustling landscape of medical technology, Penumbra Inc., founded in 2004, has etched a significant footprint by concentrating on an often-underexplored niche: therapies for neurovascular and peripheral vascular diseases. The company began its journey focusing primarily on devices to treat conditions like strokes, introducing its first product, the Penumbra System, swiftly after its inception. By innovating in thrombectomy techniques, Penumbra has provided interventionalists with the tools to effectively remove clots in the brain and restore blood flow, a crucial factor in minimizing stroke damage. The firm's pioneering spirit and commitment to addressing the unmet needs in the medical field have propelled its growth, driven by an unyielding focus on enhancing clinical outcomes for patients facing critical vascular conditions. Penumbra's success hinges not just on innovative product development but also on a comprehensive business model that centers around high-impact therapeutic solutions. It generates revenue through the sale of these specialized medical devices, primarily to hospitals and healthcare facilities across the globe. By leveraging cutting-edge technology and collaboration with healthcare professionals, Penumbra continually broadens its product portfolio, including devices for peripheral vascular interventions and embolization therapies. This focus on expanding clinical applications and adapting to emerging medical challenges ensures that Penumbra stays at the forefront of innovation, enabling it to capture a growing share of the global healthcare market. Through its focused approach, Penumbra not only makes strides in advancing medical treatments but also fortifies its position as a formidable player in the field of therapeutic medical devices.
See Also
What is Penumbra Inc's Total Receivables?
Total Receivables
167.7m
USD
Based on the financial report for Dec 31, 2024, Penumbra Inc's Total Receivables amounts to 167.7m USD.
What is Penumbra Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
10%
Over the last year, the Total Receivables growth was -17%. The average annual Total Receivables growth rates for Penumbra Inc have been 8% over the past three years , 10% over the past five years .
You don't have any saved screeners yet